Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTST CannTrust	C$0.64	C$0.64	C$0.38 ▼ C$8.17	C$90.27M	N/A	N/A	N/A
EPIX ESSA Pharma	$1.87 +0.5%	$1.71	$1.40 ▼ $7.88	$82.56M	1.56	356,913 shs	833,043 shs
ETON Eton Pharmaceuticals	$14.43 -0.8%	$16.31	$3.25 ▼ $21.48	$389.93M	1.18	270,988 shs	767,234 shs
SVRA Savara	$2.29 -8.8%	$2.47	$1.89 ▼ $5.00	$433.82M	0.31	1.27 million shs	684,196 shs
ZYNE Zynerba Pharmaceuticals	$1.30	$1.30	$0.25 ▼ $1.40	$70.12M	1.32	515,333 shs	N/A

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTST CannTrust	0.00%	0.00%	0.00%	0.00%	0.00%
EPIX ESSA Pharma	+8.77%	+9.41%	+11.38%	+14.11%	-65.43%
ETON Eton Pharmaceuticals	+0.35%	+1.04%	+1.68%	+2.47%	+326.39%
SVRA Savara	+5.02%	+7.26%	+13.57%	-14.33%	-48.67%
ZYNE Zynerba Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTST CannTrust	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPIX ESSA Pharma	1.0893 of 5 stars	1.0	2.0	0.0	0.0	2.8	2.5	1.3
ETON Eton Pharmaceuticals	2.1062 of 5 stars	3.5	1.0	0.0	0.0	2.5	1.7	0.6
SVRA Savara	2.1754 of 5 stars	3.3	0.0	0.0	0.0	2.7	3.3	0.6
ZYNE Zynerba Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTST CannTrust	0.00	N/A	N/A	N/A
EPIX ESSA Pharma	2.00	Hold	$2.00	6.95% Upside
ETON Eton Pharmaceuticals	3.00	Buy	$29.67	105.59% Upside
SVRA Savara	2.60	Moderate Buy	$5.60	144.54% Upside
ZYNE Zynerba Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest EPIX, ETON, CTST, ZYNE, and SVRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/29/2025	ETON Eton Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $35.00
5/29/2025	SVRA Savara	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$6.00 ➝ $2.00
5/28/2025	SVRA Savara	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	In-Line ➝ In-Line	$3.00 ➝ $2.00
5/28/2025	SVRA Savara	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $8.00
5/28/2025	SVRA Savara	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$8.00 ➝ $7.00
5/16/2025	ETON Eton Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $26.00
5/14/2025	ETON Eton Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$26.00 ➝ $28.00

(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTST CannTrust	C$35.22M	2.56	N/A	N/A	N/A	∞
EPIX ESSA Pharma	N/A	N/A	N/A	N/A	$2.81 per share	N/A
ETON Eton Pharmaceuticals	$39.01M	9.92	N/A	N/A	$0.94 per share	15.35
SVRA Savara	N/A	N/A	N/A	N/A	$1.00 per share	N/A
ZYNE Zynerba Pharmaceuticals	N/A	N/A	N/A	N/A	$1.01 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTST CannTrust	-C$10.46M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
EPIX ESSA Pharma	-$28.54M	-$0.63	N/A	N/A	N/A	N/A	-23.48%	-22.86%	8/4/2025 (Estimated)
ETON Eton Pharmaceuticals	-$3.82M	-$0.18	N/A	28.86	N/A	-9.49%	-3.15%	-1.08%	8/4/2025 (Estimated)
SVRA Savara	-$95.88M	-$0.48	N/A	N/A	N/A	N/A	-65.88%	-52.35%	8/11/2025 (Estimated)
ZYNE Zynerba Pharmaceuticals	-$35.04M	-$0.80	N/A	N/A	N/A	N/A	-90.03%	-72.62%	N/A

Latest EPIX, ETON, CTST, ZYNE, and SVRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q1 2025	SVRA Savara	-$0.12	N/A	N/A	N/A	N/A	N/A
8/4/2025	Q3 2025	EPIX ESSA Pharma	-$0.2430	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	ETON Eton Pharmaceuticals	$0.09	$0.07	-$0.02	-$0.06	$14.33 million	$17.28 million
5/13/2025	Q1 2025	SVRA Savara	-$0.12	-$0.12	N/A	-$0.12	N/A	N/A
5/8/2025	Q2 2025	EPIX ESSA Pharma	-$0.19	-$0.14	+$0.05	-$0.14	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTST CannTrust	N/A	N/A	N/A	N/A	N/A
EPIX ESSA Pharma	N/A	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SVRA Savara	N/A	N/A	N/A	N/A	N/A
ZYNE Zynerba Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTST CannTrust	N/A	N/A	N/A
EPIX ESSA Pharma	N/A	67.15	67.15
ETON Eton Pharmaceuticals	1.23	1.97	1.43
SVRA Savara	0.20	14.91	14.91
ZYNE Zynerba Pharmaceuticals	N/A	3.43	3.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTST CannTrust	0.03%
EPIX ESSA Pharma	75.12%
ETON Eton Pharmaceuticals	27.86%
SVRA Savara	87.93%
ZYNE Zynerba Pharmaceuticals	11.23%

Insider Ownership

Company	Insider Ownership
CTST CannTrust	N/A
EPIX ESSA Pharma	15.50%
ETON Eton Pharmaceuticals	14.89%
SVRA Savara	5.13%
ZYNE Zynerba Pharmaceuticals	13.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTST CannTrust	576	141.49 million	N/A	Optionable
EPIX ESSA Pharma	50	44.39 million	37.51 million	Optionable
ETON Eton Pharmaceuticals	20	26.82 million	22.83 million	Optionable
SVRA Savara	20	172.84 million	163.97 million	Optionable
ZYNE Zynerba Pharmaceuticals	25	53.94 million	46.91 million	Optionable

EPIX, ETON, CTST, ZYNE, and SVRA Headlines

Recent News About These Companies

22q11.2 Deletion Syndrome Market Research Report 2025: Zynerba Pharmaceuticals is at the Forefront with Its Clinical-stage Therapy Zygel (ZYN002)

June 25, 2025 | globenewswire.com

Harmony Biosciences: If It Ain't Broke

June 5, 2025 | seekingalpha.com

US Penny Stocks To Watch In October 2024

October 28, 2024 | uk.finance.yahoo.com

Discover 3 US Penny Stocks With Market Caps Over $70M

October 24, 2024 | uk.finance.yahoo.com

Atea Pharmaceuticals Leads The Charge In US Penny Stocks Spotlight

October 22, 2024 | uk.finance.yahoo.com

GW Pharma's cannabis-derived epilepsy drug approved in EU

October 7, 2024 | pharmaphorum.comP

Fragile X Syndrome Therapeutic Pipeline Research Report 2024 Featuring Zynerba, Tetra Discovery Partners, Nova Mentis, Neuren Pharmaceuticals, and Tetra Discovery Partners

July 31, 2024 | globenewswire.com

Harmony Biosciences Reports Strong Third Quarter 2023 Financial Results

October 31, 2023 | finance.yahoo.com

Why Shares of Harmony Bioscience Are Falling on Friday

October 13, 2023 | fool.com

New Possibilities For Cannabinoid Treatments: Acquisition To Transform Neuropsychiatric Disorder Therapies

October 11, 2023 | markets.businessinsider.com

HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE

October 11, 2023 | finance.yahoo.com

H.C. Wainwright analysts reiterates a Buy rating for Zynerba Pharmaceuticals Inc (ZYNE)

October 10, 2023 | knoxdaily.comK

Analysts: ZYNE stock price target of $1.25 in 12 months

October 5, 2023 | knoxdaily.comK

Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions

October 4, 2023 | finance.yahoo.com

Examining the Potential Price Growth of Zynerba Pharmaceuticals Inc (ZYNE)

October 2, 2023 | knoxdaily.comK

20 Countries With Highest Rate of Epilepsy

September 29, 2023 | finance.yahoo.com

Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023

September 29, 2023 | finance.yahoo.com

Harmony Biosciences extends deadline for Zynerba shareholders on up to $200M deal

September 27, 2023 | bizjournals.com

Zynerba Pharmaceuticals Inc [ZYNE] Investment Appeal on the Rise

September 25, 2023 | knoxdaily.comK

Zynerba Pharmaceuticals Inc. (ZYNE) rating reiterates by H.C. Wainwright

September 20, 2023 | knoxdaily.comK

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPIX, ETON, CTST, ZYNE, and SVRA Company Descriptions

CannTrust NYSE:CTST

CannTrust Holdings Inc. produces and sells medical and recreational cannabis in Canada. It sells dried cannabis and cannabis extracts to the medical patients. CannTrust Holdings Inc. was incorporated in 2015 and is headquartered in Vaughan, Canada.

ESSA Pharma NASDAQ:EPIX

$1.87 +0.01 (+0.54%)

Closing price 04:00 PM Eastern

Extended Trading

$1.86 -0.01 (-0.53%)

As of 08:00 PM Eastern

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Eton Pharmaceuticals NASDAQ:ETON

$14.43 -0.11 (-0.76%)

Closing price 04:00 PM Eastern

Extended Trading

$13.70 -0.73 (-5.09%)

As of 07:30 PM Eastern

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Savara NASDAQ:SVRA

$2.29 -0.22 (-8.76%)

Closing price 04:00 PM Eastern

Extended Trading

$2.35 +0.06 (+2.45%)

As of 07:57 PM Eastern

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

Zynerba Pharmaceuticals NASDAQ:ZYNE

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time